Valneva SE VALN has signed an advance purchase agreement with the Kingdom of Bahrain to supply one (1) million doses of its inactivated COVID-19 vaccine candidate VLA2001.
- This is the second purchase agreement Valneva has secured for VLA2001 since reporting data for its Phase 3 trial Cov-Compare.
- Valneva has initiated a rolling submission process with the Bahraini National Health Regulatory Authority.
- The Company plans to start deliveries in the Q1 of 2022.
- Last month, Valneva announced that the European Commission signed an advanced purchase agreement for up to 60 million doses of VLA20011.
- Related Link: Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population.
- Price Action: VALN shares are up 13.3% at $54.38 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechGovernmentLong IdeasNewsHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in